Skip to main content
Clinical Trials/NCT05253729
NCT05253729
Completed
Not Applicable

Efficacy of Focused Shockwave Therapy in Patients With Moderate to Severe Carpal Tunnel Syndrome, a Single-blinded Randomized Controlled Trial

Mahidol University1 site in 1 country24 target enrollmentStarted: June 1, 2018Last updated:

Overview

Phase
Not Applicable
Status
Completed
Enrollment
24
Locations
1
Primary Endpoint
Thai version of Boston Carpal Tunnel Questionnaire (T-BCTQ)

Overview

Brief Summary

Carpal tunnel syndrome (CTS) is the most common entrapment of upper extremity. Patients with CTS will experience symptoms of pain, numbness of tingling sensation along the median nerve distribution. In more severe case, patients may have difficult manipulating objects that disturb function and patient's quality of life. Extracorporeal Shockwave Therapy (ESWT) is one of physical modalities that uses to treat many musculoskeletal disorders. For CTS, previous evidence showed that ESWT can improve symptoms, function as well as electrophysiologic parameters. However, standardized guidelines as well as the study in patients with moderate to severe CTS has not been established. Thus, the objective of the present study was to evaluate efficacy of ESWT in term of symptoms, function, electrophysiologic parameters, as well as sonography of median nerve in patients with moderate to severe CTS.

Detailed Description

  • The present study was a single-blinded randomized controlled trial comparing the efficacy of focused ESWT (F-ESWT) to conservative treatment in patients with CTS.
  • 24 patients who was diagnosed as CTS based on symptoms of CTS and physical examination. They were randomly allocated into two groups (21 patients per group), mainly F-ESWT plus conservative treatment and conservative treatment only.
  • Outcome measures were BCTQ including symptom and function subscales, electrophysiologic parameters, and sonography to evaluate cross-sectional area (CSA) of the median nerve. All measures were recorded at baseline, 3 weeks and 6 weeks of treatment.
  • Statistical analysis was performed to determine changes within the same group and compare difference between the two groups.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
20 Years to 80 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Participants who were diagnosed as CTS based on the American Academy of neurology
  • Participants who have electrodiagnostic evidence of CTS according to American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) guidelines for diagnosis of CTS. The severity of median nerve compression at wrist was moderate to severe degree.
  • Patients who were not treated by NSAIDs within 2 weeks prior to participating in the study.

Exclusion Criteria

  • The below exclusion criteria were applied only on the affected hand that were enrolled to the study
  • History of previous carpal tunnel release.
  • Receiving steroid injections for the treatment of CTS
  • History of infection or severe inflammation on the wrist
  • Contraindications for focused ESWT, such as arrhythmias, pacemakers, bleeding disorders, pregnancy, severe osteoporosis, and cancer.
  • Participants who refused or requested withdrawal from the study.

Outcomes

Primary Outcomes

Thai version of Boston Carpal Tunnel Questionnaire (T-BCTQ)

Time Frame: BCTQs and BCTQf were assessed changes from baseline to at 6 weeks of treatment.

T-BCTQ was used to assess symptom severity and hand function in patients with CTS. This questionnaire consists of two parts, mainly BCTQ symptom severity (BCTQs) and BCTQ functional status (BCTQf). Total questions for each part were 11 and 8 questions, respectively with scores raging from 1-5.

Secondary Outcomes

  • Electrodiagnostic parameters: Distal Sensory Latency (DSL)(Changes of DSL was assessed from baseline to at 6 weeks of treatment.)
  • Electrodiagnostic parameters: Sensory Nerve Action Potential (SNAP) amplitude(SNAP amplitude was assessed from baseline to at 6 weeks of treatment.)
  • Electrodiagnostic parameters: Distal Motor Latency (DML)(Changes of DSL was assessed from baseline to at 6 weeks of treatment.)
  • Electrodiagnostic parameters: Compound Muscle Action Potential (CMAP) amplitude(Changes of CMAP amplitude was assessed from baseline to at 6 weeks of treatment.)
  • Electrodiagnostic parameters: Total area under curve (TAUC)(Changes of TAUC was assessed from baseline to at 6 weeks of treatment.)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials